Keep pulling the thread on Vicarious Surgical.
As of mid-2024, Vicarious Surgical is still a pre-revenue company.
Since Nanolize's coverage in 2021, Vicarious Surgical's stock has lost 99% of its value.
BioNanogenomics' stock price jumped over 2,000% in 60 days following a public interaction between an ARK analyst and the company.
BioNanogenomics has a market capitalization of $15 million despite having $28 million in annual revenues and 50% gross margins.
BioNanogenomics is running out of capital, which severely limits its options to raise money through equity or debt.
One week after announcing an expanded collaboration, United Therapeutics terminated its licensing agreement with Coalplant.
Vicarious Surgical's original product roadmap projected the shipment of 100 units by the end of 2024.
Vicarious Surgical's market capitalization has fallen to $14 million.
Over the same period that Vicarious Surgical stock fell 99%, Intuitive Surgical stock gained 115%, outperforming the S&P 500's 87% gain.
Intuitive Surgical currently has a simple valuation ratio (market cap divided by annualized revenues) of 20.5, which is slightly above Nanolize's target of 20.
Since Nanolize identified a hype event, shares of BioNanogenomics have lost 97% of their value.
Nanolize believes Illumina is not interested in acquiring BioNanogenomics, arguing Illumina would have already explored the optical genome mapping space if it were a significant opportunity.